Collaborators and Partners | Partners | Tekmira Pharmaceuticals

Since inception, Tekmira has fostered collaborations and partnerships with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals Inc., Merck & Co. Inc., Takeda Pharmaceutical Company, US Department of Defense's BioDefense Therapeutics Program, Monsanto, and other undisclosed pharmaceutical and biotechnology companies.

Our Partners

	Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) Tekmira has granted a license to Alnylam to use Tekmira's LNP technology to enable RNAi therapeutic products. Tekmira will receive milestone and royalty payments as LNP-enabled products are developed and commercialized. Alnylam currently has three LNP-enabled products in human clinical trials: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02. Read more about Tekmira’s Partnered Products here.
	Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) In November 2014, Tekmira signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. to license Tekmira's LNP delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program. Dicerna will use Tekmira's third generation LNP technology to deliver DCR-PH1, for the treatment of PH1, a rare inherited liver disorder that often results in kidney failure and for which there are no approved therapies. Tekmira will provide clinical drug supply and regulatory support to advance DCR-PH1.
	US Department of Defense's BioDefense Therapeutics, a Joint Product Manager within the Medical Countermeasure Systems In 2010, Tekmira signed a $140-million contract with with the US Department of Defense's (DoD) BioDefense Therapeutics (BDTX), a Joint Product Manager within the Medical Countermeasure Systems (JPM-MCS) Joint Project Management Office, to advance an RNAi therapeutic utilizing Tekmira’s LNP technology to treat Ebola virus infection. In 2013, the collaboration was expanded to include significant advances in LNP formulation technology, including a new LNP formulation that was more potent, the ability to be able to lyophilize (freeze-dry) LNP formulations. In 2014, Tekmira commenced TKM-Ebola Phase I clinical trial. Additionally, in 2014, the DoD exercised an option to scale up and GMP manufacture TKM-Ebola-Guinea. JPM-MCS, a component of the Joint Program Executive Office for Chemical and Biological Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. JPM-MCS facilitates the advanced development and acquisition of medical countermeasures and systems to enhance U.S. biodefense response capability. For more information, visit www.jpeocbd.osd.mil.
	Arcturus Therapeutics Inc. (Marina Biotech Inc.) In 2012, Tekmira obtained a worldwide, non-exclusive license to a novel RNAi trigger technology called Unlocked Nucleobase Analog (UNA) from Marina Biotech for the development of RNAi therapeutics. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects. Read more about RNA Trigger Technologies here. In October of 2013, Marina assigned its rights and obligations to Arcturus, including Tekmira’s license to the UNAs.
	Monsanto Company In 2014, Tekmira signed an Option Agreement with Monsanto, permitting Monsanto to obtain a license to use Tekmira's proprietary delivery technology. The companies' agreement and research collaboration will focus on the development of new innovative biological solutions for farmers, which have the potential to provide new options for sustainable pest, virus and weed control. The potential value of the transaction could reach up to $86.2 million following the successful completion of milestones.
	Spectrum Pharmaceuticals, Inc. In 2006, Tekmira licensed three liposomal chemotherapy products to Talon Therapeutics: Marqibo® (a liposomal formulation of the chemotherapy drug vincristine); Alocrest (a liposomal formulation of the chemotherapy drug vinorelbine); and, Brakiva (a liposomal formulation of the chemotherapy drug topotecan). In 2013, Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) acquired Talon Therapeutics. Spectrum has launched Marqibo® through its existing hematology sales force. Tekmira receives royalty payments based on Marqibo®’s commercial sales.

Read more about our Partnered Products here.